PDUFA III Or Hatch/Waxman II?: Payors Urge Fix For Generic “Loopholes”
This article was originally published in The Tan Sheet
Executive Summary
Supporters of the generic industry's Hatch/Waxman agenda are eyeing the Prescription Drug User Fee Act reauthorization as a potential vehicle for reform measures